NCT07198932 (COLOR-REAL) is a clinical trial of Cofrogliptin add to insulin in Type 2 Diabetes, sponsored by Yanbing Li.

Who is sponsoring NCT07198932?

NCT07198932 is sponsored by Yanbing Li.

What drugs are being tested in NCT07198932?

Interventions in NCT07198932: Cofrogliptin add to insulin, Linagliptin add to insulin.

What condition does NCT07198932 study?

NCT07198932 studies Type 2 Diabetes.

Is NCT07198932 still recruiting?

NCT07198932 is currently not yet recruiting. Last updated 30 September 2025.

Last reviewed 2025-09-30 · How we verify

NCT07198932: COLOR-REAL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Cofrogliptin and Linagliptin as add-on Therapy to Insulin in Type 2 Diabetes

Not yet recruiting Last updated 30 September 2025

What this trial tests

trial testing Cofrogliptin add to insulin in Type 2 Diabetes in 594 participants. Not yet recruiting.

Timeline

1 October 2025

Primary endpoint
31 July 2027

31 December 2027

Quick facts

Lead sponsor	Yanbing Li
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	594
Start date	1 October 2025
Primary completion	31 July 2027
Estimated completion	31 December 2027
Sites	7 locations across China

Drugs / interventions tested

Cofrogliptin add to insulin — full drug profile →
Linagliptin add to insulin — full drug profile →

Conditions studied

Type 2 Diabetes — all drugs for Type 2 Diabetes →

Sponsor

Yanbing Li — full company profile →

Who can join

18 and older, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a multicenter, prospective, non-interventional real-world study to evaluate the clinical outcomes of biweekly cofrogliptin versus daily linagliptin as an add-on therapy in Chinese adult T2D patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Type 2 Diabetes

Currently open trials in the same condition.

NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
NCT07254689 — The Food for Health Study · NA · recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Other Yanbing Li trials

Trials by the same sponsor.

NCT07173712 — Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes · Phase 4 · not yet recruiting
NCT06007014 — Efficacy and Safety of Chiglitazar Added to Glargine in Patients With Type 2 Diabetes · NA · unknown
NCT03958591 — Effects of Short-term Intensive De-escalation Therapy on Long-term Regimen Simplification · Phase 4 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07198932 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yanbing Li
Last refreshed: 30 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07198932.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing